Rectal aminophylline in the management of apnoea of prematurity

A J LYON AND N McINTOSH

Neonatal Unit, St George’s Hospital, London

SUMMARY Rectal suppositories as an alternative to intravenous aminophylline in the management of recurrent apnoea were studied in 41 preterm infants of mean gestation 28·3 weeks and mean birthweight 1176 g. Therapeutic blood concentrations were obtained two hours after a rectal loading dose of 10 mg/kg, with steady concentrations and maximum reduction in apnoeic episodes (from a mean of 0·5 per hour to 0·09 per hour) within 24 hours on a maintenance dose of 10 mg/kg/day. There was good correlation between the rectal dose and the plasma theophylline concentration. Several infants showed a significant reduction in PCO₂ when treated with aminophylline. Side effects were related to the plasma theophylline concentration and were not seen at concentrations less than 14 mg/l.

Methylxanthines are effective in the management of apnoea of prematurity. Dosage schedules for intravenous aminophylline have been reported, but repeated venous access can be a problem in the preterm neonate if no intravenous line is in situ. Oral preparations are absorbed erratically and have possible gastrointestinal side effects.

There have been reports of unpredictable blood concentrations and deaths in children and adults using aminophylline suppositories in the treatment of asthma. In the apnoeic neonate, however, aminophylline suppositories have been effective, but neither blood concentrations nor any assessment of toxic effects have been reported.

The policy at this hospital has been to use an intravenous loading dose of aminophylline followed by maintenance treatment with suppositories. The intravenous dose has often been omitted, however, if no intravenous line has been available.

This study aimed to evaluate clinical experience with aminophylline suppositories in the management of apnoea of prematurity and to obtain pharmacokinetic data for this preparation. In particular, suppositories were compared with intravenous aminophylline as an effective means of administering a loading dose of theophylline.

Patients and methods

To determine the optimum maintenance dose of rectal aminophylline the plasma theophylline concentrations achieved in 40 infants on varying doses were obtained retrospectively from hospital notes; all concentrations were determined after the baby had been on aminophylline for at least 48 hours. The concentrations were plotted against dose and the regression line calculated by the method of least squares.

Forty one preterm infants (gestation, mean (SD) 28·3 (2·2) weeks; birthweight, mean (SD) 1176 (350) g) with recurrent apnoea, defined as cessation of respiration for 20 seconds with associated bradycardia or cyanosis, were then studied prospectively.

Three groups of similar gestation, birthweight, and age at start of treatment were compared:

(a) No loading dose (n=17).
(b) Rectal loading dose 10 mg/kg (n=12).
(c) Intravenous loading dose 6 mg/kg (n=12).

Starting four hours after the loading dose, maintenance treatment in all three groups was with aminophylline suppositories (Macarthy Ltd), 10 mg/kg/day in three or four divided doses. The suppositories were held in the rectum by a finger over the anus until dissolved, usually in one to two minutes.

Theophylline concentrations in plasma were determined using an enzyme multiplied immunoassay technique (EMIT, SYVA Chemicals). Blood (0·5 ml) for plasma theophylline determinations was taken at one, two, and three hours after the loading dose, before maintenance treatment had begun, and then at 24 hours and 48 hours after starting this. Plasma concentrations were checked further, as necessary, for therapeutic monitoring, the dose...
being altered to keep the concentrations between 6 and 13 mg/l.

After treatment for at least 48 hours, the plasma concentrations in five infants were determined immediately before and at one and two hours after a suppository, to check for variability in concentrations at different times after a dose. In these same infants the half life of theophylline was calculated from concentrations 12 and 36 hours after stopping treatment.

Six infants had \( \text{Paco}_2 \) values recorded before and after treatment with aminophylline and three other babies had continuous transcutaneous \( \text{CO}_2 \) recordings, linked to a computer based monitoring system, over the period that treatment was started.

All side effects related to aminophylline were noted.

**Results**

The relation between plasma theophylline concentrations and dose for the retrospective analyses of the hospital notes of 40 infants is shown in Fig. 1. Concentrations while on different dosages were determined in six babies, and in each of these the correlation coefficient for plasma concentration and dose was between 0.76 and 0.95.

After the intravenous and rectal loading doses, maximum concentrations were achieved by two hours. The Table shows the mean plasma concentrations and numbers of apnoeic episodes, at two, 24, and 48 hours after starting treatment with aminophylline for each group.

In the groups (b) and (c), who received a loading dose, similar therapeutic concentrations were obtained by two hours, with steady concentrations and maximum effect achieved within 24 hours. In group (a) with no loading dose, the steady state and maximum therapeutic effect were still not obtained by 48 hours.

After treatment for at least 48 hours with a particular dose, there were no significant differences between the plasma concentrations taken at varying times after a dose. The half lives calculated from concentrations after treatment ranged from 23 to 37 hours.

Figure 2 shows the effect of aminophylline on \( \text{Paco}_2 \) values in four infants who responded to treatment and in two who showed no reduction in apnoeic episodes despite therapeutic blood concentrations. Continuous monitoring of transcutaneous \( \text{Paco}_2 \) showed similar changes in transcutaneous \( \text{Paco}_2 \) after treatment with theophylline.

Toxic effects were recorded in 14 infants. These were related to the plasma concentrations and were not found at concentrations less than 14 mg/l. Twelve developed a tachycardia (greater than 170/minute), six had glycosuria, and one infant became hyponaetraemic. In two patients increased jitteriness and fits were recorded with plasma concentrations of 14.5 and 17 mg/l.

An increase in basal heart rate occurred in all treated infants, and the rise correlated significantly

![Fig. 1 Relation between plasma concentration of theophylline (mg/l) and dose (mg/kg/d).](http://adc.bmj.com/)
with the concentration of theophylline (r=0.65
P<0.05). A rise of greater than 20 beats/minute was
seen in 12 of 14 infants with concentrations greater
than 14 mg/l, but in only one of 20 with a
concentration less than 14 mg/l (Fig. 3).

No local side effects of the suppositories were
noted.

Discussion

Aminophylline suppositories proved an effective
and safe means of administering theophylline to
preterm neonates. The absorption was rapid, with
therapeutic concentrations achieved within two
hours of a loading dose of 10 mg/kg. The correlation
of plasma concentrations and dose was much better
than that found in older children and adults, and
possibly reflects a more controlled method of
administration.

One of the major problems with suppositories is
the difficulty in tailoring the dose to the needs of the
individual. In most infants, therapeutic concentra-
tions were maintained using 10 mg/kg/day and this
dose was achieved with a combination of 3 and 5 mg
suppositories given three or four times a day. The
long half life of theophylline in preterm infants
means that even if given eight hourly, there will be
very little change in concentration between doses.
Good concentrations and response were achieved by
a twice daily suppository in two infants. The
manufacturers will supply suppositories of any
required strength.

Theophylline improves respiratory drive, prob-
ably by increasing the sensitivity of the respiratory
centre to CO2. This increase in respiratory drive is
shown by the reduction in Pco2 after treatment.

All preterm infants being treated with aminophyl-
line should have the plasma concentration deter-
mined regularly for therapeutic monitoring. Even in
the best centres, however, there can be a substantial
delay in obtaining results from the laboratory. An
increase in basal heart rate greater than 20 beats/
minute is an indication that the plasma concentra-
tion may be in the toxic range.

Aminophylline suppositories used in the manage-
ment of apnoea of prematurity are as effective as,
and a safe and convenient alternative to, the
intravenous preparation.

We thank the nursing and medical staff on the Neonatal Unit for
care and cooperation in managing these small infants and Mrs S
Garrett, Mrs J Lyon, and Mrs V Williams for secretarial help.

References

1 Kuzenko JA, Paala J. Apnoeic attacks in the newborn treated
2 Shannon DC, Gotay F, Stein IM, et al. Prevention of apnoea and
3 Jones RAK, Baillie E. Dosage schedule for intravenous
aminophylline in apnoea of prematurity, based on phar-mokinetic
4 Aranda JV, Sitar DS, Parsons WD, Loughnan PM, Neims AH.
Pharmacokinetic aspects of theophylline in premature new-
5 Rounds VI. Aminophylline poisoning. Pediatrics 1954;14:
528-31.
6 Nolke AC. Severe toxic effects of aminophylline and theophyl-
7 Bednarek FJ, Roloff DW. Treatment of apnoea of prematurity
Rectal aminophylline in the management of apnoea of prematurity


Correspondence to Dr N McIntosh, Neonatal Unit, St George’s Hospital, London SW17 0QT.